European Journal of Chemistry 2018, 9(4), 331-337. doi:10.5155/eurjchem.9.4.331-337.1753

Spectrofluorimetric determination of Bisoprolol fumarate and Rosuvastatin calcium in a novel combined formulation and in human spiked plasma


Nada Sayed Abdelwahab (1) orcid , Nouruddin Wageh Ali (2) orcid , Marco Mounir Zaki (3,*) orcid , Adel Ahmed Ali (4) orcid , Mohamed Mohamed Abdelkawy (5) orcid

(1) Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt
(2) Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt
(3) Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt
(4) Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt
(5) Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
(*) Corresponding Author

Received: 03 Jun 2018, Accepted: 10 Aug 2018, Published: 31 Dec 2018

Abstract


Sensitive, simple and rapid spectrofluorimetric method was developed for simultaneous determination of bisoprolol fumarate (BIS) and rosuvastatin calcium (ROS) in novel formulated tablets and in human spiked plasma depending on measuring their native fluorescence. The fluorescence intensity of BIS and ROS were measured in methanol at emission wavelength of 297 and 485 nm upon excitation at 227 and 242 nm, respectively. The emission spectrum of each drug reveals zero value at the emission wavelength of the other drug, thus allowing their simultaneous determination without any interference and without using any tedious derivatization steps. Excellent linearity was obtained over the range of 10-500 and 20-1000 ng/mL for BIS and ROS, respectively. The developed method was evaluated by applying to laboratory prepared mixtures and pharmaceutical formulation. The high sensitivity of the method was the motivation to its application for analysis of the cited drugs in spiked human plasma. Likewise, analytical and bioanalytical method validation was carried out following International Conference on Harmonisation guidelines and also statistical analysis with the reported methods was carried out and no significant difference was found. The developed method is the first developed spectrofluorimetric method for simultaneous determination of the newly formulated drugs.


Keywords


Tablets; Bisoprolol; Rosuvastatin; Novel formulation; Spectrofluorimetry; Spiked human plasma

Full Text:

PDF /    /


DOI: 10.5155/eurjchem.9.4.331-337.1753

Article Metrics


This Abstract was viewed 236 times | PDF Article downloaded 54 times

Citations

/


[1]. Marco Mounir Zaki, Nada Sayed Abdelwahab, Adel Ahmed Ali, Souty Mounie Zaki Sharkawi
Simultaneous determination of bisoprolol fumarate and rosuvastatin calcium in a new combined formulation by validated RP-HPLC
European Journal of Chemistry  10(1), 52, 2019
DOI: 10.5155/eurjchem.10.1.52-56.1815
/


References

[1]. The British Pharmacopoeia, Volumes II and III, Her Majesty's Stationery Office, London, UK. 2009.

[2]. Sweetman, S. C.; Martindale, The complete drug reference, 36th Edition, London; Chicago: Pharmaceutical Press, 2009.

[3]. United States Food and Drug Administration. Crestor (rosuvastatin calcium) Tablets. Prescribing Information Label. 2012; Available online: http://www. accessdata.fda.gov/drugsatfda_docs/label/ 2012/021366s026lbl.pdf (Accessed on 01 August 2018).

[4]. Bondjers, G.; Wiklund O.; Wikstrand J. Patent application number: US10/220, 790, Publication number: US20030060477-A1, Publication date: Mar 27, 2003. Available online: 3 July 2017 at https://www.google.com/patents/US20030060477?cl=en10 (Accessed on 01 August 2018)

[5]. Salem, H. J. Pharm. Biomed. Anal. 2002, 29, 527-538.
https://doi.org/10.1016/S0731-7085(02)00100-0

[6]. Tuljarani, G.; Sankar, D. G.; Kadgapathi, P.; Suthakaran, R.; Satyanarayana, B. Int. J. Chem. Sci. 2010, 8, 2253-2258.

[7]. Shirkhedkar, A. A.; Thorve, R. R.; Surana, S. J. Pakistan J. Pharm. Sci. 2008, 21, 366-369.

[8]. Abdelmonem, A. A.; Ragab, H. G.; Hashem, H.; Bahgat, E. A. UK J. Pharm. Biosci. 2016, 4, 43-52.
https://doi.org/10.20510/ukjpb/4/i2/97093

[9]. Goyal, R. N.; Tyagi, A.; Bachheti, N.; Bishnoi, S. Electrochim. Acta 2008, 53, 2802-2808.
https://doi.org/10.1016/j.electacta.2007.10.057

[10]. Kakde, R. B.; Kotak, V. H.; Kale, D. L. Asian J. Res. Chem. 2008, 1, 70-73.

[11]. Pradip, N. B.; Emanual, M. P.; Gautambhai. J. Chromatogr. Sep. Tech. 2013, 4, 1-4.

[12]. Savita, S. Y.; Janhavi, R. R. Int. J. Pharm. Pharma. Sci. 2013, 5, 286-290.

[13]. United States Pharmacopoeia, XXIV, United States Pharmacopoeia Convention, Washington, DC, 2007.

[14]. Shaikh, S.; Thusleem, O. A.; Muneera, M. S.; Akmal, J.; Kondaguli, A. V.; Ruckmani, K. A. J. Pharm. Biomed. Anal. 2008, 48, 1055-1057.
https://doi.org/10.1016/j.jpba.2008.08.009

[15]. Hefnawy, M. M.; Sultan, M. A.; Al-Shehri, M. M. J. Liq. Chromatogr. Relat. Technol. 2006, 29, 2901-2914.
https://doi.org/10.1080/10826070600978302

[16]. Athota, R. V.; Jagarlapudi, S. K.; Singampalli, M. R. Int. J. Pharm. Tech. Res. 2016, 9, 329-339.

[17]. Erdal, D.; Zehra, C. E.; Ghazal, R. J. Liq. Chromatogr. Relat. Technol. 2015, 38, 970-976.
https://doi.org/10.1080/10826076.2014.999200

[18]. Sevinc, K.; Paula, R. S. M.; Bengi, U.; Sibel, A. O. Chromatographia 2014, 77, 365-371.
https://doi.org/10.1007/s10337-013-2606-4

[19]. Tutunji, M. F.; Ibrahim, H. M.; Khabbas, M. H.; Tutunji, L. F. J. Chromatogr. B 2009, 877, 1689-1697.
https://doi.org/10.1016/j.jchromb.2009.04.021

[20]. Arjun, S.; Sivakumar, T.; Jain, D. A.; Umesh, M.; Arun, K. Y.; Tarun, S. Int. J. Pharm. Res. Dev. 2011, 3, 1-3.

[21]. Baldut, M.; Bonafede, S. L.; Petrone, L.; Simionato, L. D.; Segall, A. I. Adv. Res. 2015, 5, 1-8.
https://doi.org/10.9734/AIR/2015/19843

[22]. Rekha, R.; Anbazhagan, S.; Kumar, P. R. Int. J. Pharm. Tech. Res. 2012, 4, 1601-1605.

[23]. Jain, P. S.; Kale, N. K.; Surana, S. J. J. Pharm. Biosci. 2013, 4, 128-133.

[24]. Gupta, A.; Mishra, P.; Shah, K. E-J. Chem. 2009, 6, 89-92.
https://doi.org/10.1155/2009/956712

[25]. Garg, S. Acta Velit. 2014, 1, 20-24.

[26]. Alzoman, N. Z.; Sultan, M. A.; Maher, H. M.; Alshehri, M. M.; Wani, T. A.; Darwish, I. A. Molecules 2013, 18, 7711-7725.
https://doi.org/10.3390/molecules18077711

[27]. Ramadan, A. A.; Mandil, H.; Alshelhawi, N. Int. J. Pharm. Pharma. Sci. 2014, 6, 579-585.

[28]. Krishna, M. V.; Sankar, D. G. E-J. Chem. 2007, 4, 46-49.
https://doi.org/10.1155/2007/454853

[29]. Braga, V. S. M.; Mancilha, T. P.; Cassella, R. J.; Pacheco, W. F. J. Fluoresc. 2013, 23, 49-55.
https://doi.org/10.1007/s10895-012-1115-4

[30]. Nadia, M. M.; Amr, M. B.; Nesrine, T. L.; Abd El-Aleem, A. B. J. Liq. Chromatogr. Relat. Technol. 2014, 37, 2182-2196.
https://doi.org/10.1080/10826076.2013.828305

[31]. Sane, R.; Kamat, S.; Menon, S.; Inamdar, S.; Mote, M. J. Planar Chromatogr. Mod. TLC 2005, 18, 194-198.
https://doi.org/10.1556/JPC.18.2005.3.4

[32]. Ramadan, A. A.; Hussen, A.; Maktabi, M. Int. J. Pharm. Pharm. Sci. 2014, 6, 180-188.

[33]. Devi, S. U.; Latha, E. P.; Guptha, C. V. N. K.; Ramalingam, P. Int. J. Pharma. Bio. Sci. 2011, 2, 134-140.

[34]. Shekhar, M. C.; Babu, G. R.; Dinda, S. C.; Sonthosh, P. V.; Shwetha, P. Int. J. Pharm. 2014, 4, 335-339.

[35]. Palvai, S.; Seelam, S. C.; Dhanalakshmi, K.; Reddy, N. Int. J. Pharm. Technol. 2013, 4, 182-187.

[36]. Caglar, S .; Toker, S. J. Chrom. Sci. 2013, 51, 53-58.
https://doi.org/10.1093/chromsci/bms105

[37]. Turabi, Z. M.; O'hood, A. K. ‎Int. J. Pharm. Sci. Drug Res. 2014, 6, 154-159.

[38]. Banker, G.; Anderson, N. R. Tablets (Chap. 11). In: The Theory and practice of industrial pharmacy, 3rd Ed. , Lachman, L.; Lieberman, H. A.; Kanig, J. L. (Eds), Lea and Febiger, Philadelphia, P. A. 1986, pp. 294.

[39]. Fiese, E. F.; Hagen, T. A. Preformulation (Chap. 8). In: The Theory and practice of industrial pharmacy, 3rd Ed. , Lachman, L.; Lieberman, H. A.; Kanig, J. L. (Eds), Lea and Febiger, Philadelphia, P. A. 1986, pp. 171.

[40]. Bakan, J. A. Capsules (Chap. 13), Part three microencapsulation. In: The Theory and practice of industrial pharmacy, 3rd Ed. , Lachman, L.; Lieberman, H. A.; Kanig, J. L. (Eds), Lea and Febiger, Philadelphia, P. A. 1986, pp. 412.

[41]. International Conference on Harmonization Q2 (R1), Validation of analytical procedures: Text and methodology, ICH Harmonized Tripartite Guideline, 2005.


How to cite


Abdelwahab, N.; Ali, N.; Zaki, M.; Ali, A.; Abdelkawy, M. Eur. J. Chem. 2018, 9(4), 331-337. doi:10.5155/eurjchem.9.4.331-337.1753
Abdelwahab, N.; Ali, N.; Zaki, M.; Ali, A.; Abdelkawy, M. Spectrofluorimetric determination of Bisoprolol fumarate and Rosuvastatin calcium in a novel combined formulation and in human spiked plasma. Eur. J. Chem. 2018, 9(4), 331-337. doi:10.5155/eurjchem.9.4.331-337.1753
Abdelwahab, N., Ali, N., Zaki, M., Ali, A., & Abdelkawy, M. (2018). Spectrofluorimetric determination of Bisoprolol fumarate and Rosuvastatin calcium in a novel combined formulation and in human spiked plasma. European Journal of Chemistry, 9(4), 331-337. doi:10.5155/eurjchem.9.4.331-337.1753
Abdelwahab, Nada, Nouruddin Wageh Ali, Marco Mounir Zaki, Adel Ahmed Ali, & Mohamed Mohamed Abdelkawy. "Spectrofluorimetric determination of Bisoprolol fumarate and Rosuvastatin calcium in a novel combined formulation and in human spiked plasma." European Journal of Chemistry [Online], 9.4 (2018): 331-337. Web. 26 Apr. 2019
Abdelwahab, Nada, Ali, Nouruddin, Zaki, Marco, Ali, Adel, AND Abdelkawy, Mohamed. "Spectrofluorimetric determination of Bisoprolol fumarate and Rosuvastatin calcium in a novel combined formulation and in human spiked plasma" European Journal of Chemistry [Online], Volume 9 Number 4 (31 December 2018)

DOI Link: https://doi.org/10.5155/eurjchem.9.4.331-337.1753

Refbacks





Copyright (c) 2018 Authors

Creative Commons License
This work is published and licensed by Atlanta Publishing House LLC, Atlanta, GA, USA. The full terms of this license are available at http://www.eurjchem.com/index.php/eurjchem/pages/view/terms and incorporate the Creative Commons Attribution-Non Commercial (CC BY NC) (International, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0). By accessing the work, you hereby accept the Terms. This is an open access article distributed under the terms and conditions of the CC BY NC License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited without any further permission from Atlanta Publishing House LLC (European Journal of Chemistry). No use, distribution or reproduction is permitted which does not comply with these terms. Permissions for commercial use of this work beyond the scope of the License (http://www.eurjchem.com/index.php/eurjchem/pages/view/terms) are administered by Atlanta Publishing House LLC (European Journal of Chemistry).


© Copyright 2019  Atlanta Publishing House LLC All Right Reserved.

The opinions expressed in all articles published in European Journal of Chemistry are those of the specific author(s), and do not necessarily reflect the views of Atlanta Publishing House LLC, or European Journal of Chemistry, or any of its employees.

Copyright 2019 Atlanta Publishing House LLC. All rights reserved. This site is owned and operated by Atlanta Publishing House LLC whose registered office is 4614 Lavista road, Tucker, GA, 30084, USA. Registered in USA.